Cellares raises $255M as it boosts its own manufacturing efforts
Cellares, which is known for producing the technology used in cell therapy manufacturing, has raised $255 million in a Series C as it aims to build out its own manufacturing business.
The company’s thinking is that contract manufacturers are not currently able to meet global demand, which has created a need for more CDMOs with the technical know-how to manufacture cell therapies, Cellares CEO Fabian Gerlinghaus told Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.